Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Feb 12, 2015 2:39pm

159 Views

Post# 23423268

RE:Unofficial and Uncleaned - Transcript of Yesterday's Talk

Imtesty, thank you for your effort. Very much appreciated!

I find that when I listen to the webcasts I try to keep pace and make notes becasue they full of key information but it all goes by too quickly. Then they remove the webcast at some point and all of the information is lost.

I cannot, for the life of me, understand why the RVX PR and communications team is not using communications experts to feed the information back in bite sized pieces through blogs and press releases and whatever form. Why do they make it like pulling teeth?

Thanks again because you are doing what RVX should be doing!
Cheers
Toinv

Bullboard Posts

How one company is disrupting PoC testing